Target intelligence / Profile preview

NK cell activity-associated long non-coding RNA 1 (NCAL1)

Target
NCAL1
Molecular classification
Long non-coding RNA (lncRNA), Epigenetic regulator
01

Overview

NK cell activity-associated long non-coding RNA 1 (NCAL1) is a lncRNA highly enriched in NK cells, localized mainly in the nucleus. NCAL1 enhances the cytotoxicity of NK cells against tumor cells by directly binding to the promoter region of the Gab2 scaffold protein, promoting demethylation and recruitment of the Sp1 transcription factor. This leads to increased Gab2 expression, which activates the PI3K–AKT signaling pathway, a key axis for NK cell effector functions. NCAL1 is a promising therapeutic target for boosting NK cell anti-tumor activity and improving the efficacy of NK cell-based immunotherapies.

Other names
NCAL1NK cell activity-associated lncRNA 1
02

Mechanism of action

Epigenetic modification of the Gab2 promoter: demethylation, Sp1 transcription factor recruitment, histone modification. Activation of Gab2–PI3K–AKT axis in NK cells, promoting tumor cell killing.

03

Biological functions

Immune response (enhances NK cell cytotoxicity)Epigenetic regulation (modifies methylation status of the Gab2 promoter)Signal transduction (through Gab2 and PI3K–AKT pathway)
04

Disease associations

Cancer (increased NK cell cytotoxicity toward tumor cells)Potential biomarker or target in immunotherapy
05

Safety considerations

Potential challenges in precisely modulating immune activity without triggering autoimmunity or off-target cytotoxicity (inferred from the general risks of immunotherapies; no specific safety concerns for NCAL1 reported yet)
06

Biomarkers

NCAL1 itself may be a biomarker for enhanced NK cell cytotoxicity or therapeutic response in adoptive NK cell therapiesGab2 activation status or downstream PI3K–AKT pathway activation may serve as mechanistic biomarkers

Beyond the preview

Go deeper on NK cell activity-associated long non-coding RNA 1 (NCAL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK cell activity-associated long non-coding RNA 1 (NCAL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call